Cargando…

Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis

BACKGROUND: Previous researches pointed out that the measurement of urine fibronectin (Fn) could be a potential diagnostic test for bladder cancer (BCa). We conducted this meta-analysis to fully assess the diagnostic value of urine Fn for BCa detection. METHODS: A systematic literature search in Pub...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Fan, Shen, Yifan, Xu, Tianyuan, Wang, Xianjin, Gao, Fengbin, Zhong, Shan, Chen, Shanwen, Shen, Zhoujun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863379/
https://www.ncbi.nlm.nih.gov/pubmed/29562940
http://dx.doi.org/10.1186/s12957-018-1358-x
_version_ 1783308375984963584
author Dong, Fan
Shen, Yifan
Xu, Tianyuan
Wang, Xianjin
Gao, Fengbin
Zhong, Shan
Chen, Shanwen
Shen, Zhoujun
author_facet Dong, Fan
Shen, Yifan
Xu, Tianyuan
Wang, Xianjin
Gao, Fengbin
Zhong, Shan
Chen, Shanwen
Shen, Zhoujun
author_sort Dong, Fan
collection PubMed
description BACKGROUND: Previous researches pointed out that the measurement of urine fibronectin (Fn) could be a potential diagnostic test for bladder cancer (BCa). We conducted this meta-analysis to fully assess the diagnostic value of urine Fn for BCa detection. METHODS: A systematic literature search in PubMed, ISI Web of Science, EMBASE, Cochrane library, and CBM was carried out to identify eligible studies evaluating the urine Fn in diagnosing BCa. Pooled sensitivity, specificity, and diagnostic odds ratio (DOR) with their 95% confidence intervals (CIs) were calculated, and summary receiver operating characteristic (SROC) curves were established. We applied the STATA 13.0, Meta-Disc 1.4, and RevMan 5.3 software to the meta-analysis. RESULTS: Eight separate studies with 744 bladder cancer patients were enrolled in this meta-analysis. The pooled sensitivity, specificity, and DOR were 0.80 (95%CI = 0.77–0.83), 0.79 (95%CI = 0.73–0.84), and 15.18 (95%CI = 10.07–22.87), respectively, and the area under the curve (AUC) of SROC was 0.83 (95%CI = 0.79–0.86). The diagnostic power of a combined method (urine Fn combined with urine cytology) was also evaluated, and its sensitivity and AUC were significantly higher (0.86 (95%CI = 0.82–0.90) and 0.89 (95%CI = 0.86–0.92), respectively). Meta-regression along with subgroup analysis based on various covariates revealed the potential sources of the heterogeneity and the detailed diagnostic value of each subgroup. Sensitivity analysis supported that the result was robust. No threshold effect and publication bias were found in this meta-analysis. CONCLUSIONS: Urine Fn may become a promising non-invasive biomarker for bladder cancer with a relatively satisfactory diagnostic power. And the combination of urine Fn with cytology could be an alternative option for detecting BCa in clinical practice. The potential value of urine Fn still needs to be validated in large, multi-center, and prospective studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12957-018-1358-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5863379
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58633792018-03-27 Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis Dong, Fan Shen, Yifan Xu, Tianyuan Wang, Xianjin Gao, Fengbin Zhong, Shan Chen, Shanwen Shen, Zhoujun World J Surg Oncol Research BACKGROUND: Previous researches pointed out that the measurement of urine fibronectin (Fn) could be a potential diagnostic test for bladder cancer (BCa). We conducted this meta-analysis to fully assess the diagnostic value of urine Fn for BCa detection. METHODS: A systematic literature search in PubMed, ISI Web of Science, EMBASE, Cochrane library, and CBM was carried out to identify eligible studies evaluating the urine Fn in diagnosing BCa. Pooled sensitivity, specificity, and diagnostic odds ratio (DOR) with their 95% confidence intervals (CIs) were calculated, and summary receiver operating characteristic (SROC) curves were established. We applied the STATA 13.0, Meta-Disc 1.4, and RevMan 5.3 software to the meta-analysis. RESULTS: Eight separate studies with 744 bladder cancer patients were enrolled in this meta-analysis. The pooled sensitivity, specificity, and DOR were 0.80 (95%CI = 0.77–0.83), 0.79 (95%CI = 0.73–0.84), and 15.18 (95%CI = 10.07–22.87), respectively, and the area under the curve (AUC) of SROC was 0.83 (95%CI = 0.79–0.86). The diagnostic power of a combined method (urine Fn combined with urine cytology) was also evaluated, and its sensitivity and AUC were significantly higher (0.86 (95%CI = 0.82–0.90) and 0.89 (95%CI = 0.86–0.92), respectively). Meta-regression along with subgroup analysis based on various covariates revealed the potential sources of the heterogeneity and the detailed diagnostic value of each subgroup. Sensitivity analysis supported that the result was robust. No threshold effect and publication bias were found in this meta-analysis. CONCLUSIONS: Urine Fn may become a promising non-invasive biomarker for bladder cancer with a relatively satisfactory diagnostic power. And the combination of urine Fn with cytology could be an alternative option for detecting BCa in clinical practice. The potential value of urine Fn still needs to be validated in large, multi-center, and prospective studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12957-018-1358-x) contains supplementary material, which is available to authorized users. BioMed Central 2018-03-21 /pmc/articles/PMC5863379/ /pubmed/29562940 http://dx.doi.org/10.1186/s12957-018-1358-x Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Dong, Fan
Shen, Yifan
Xu, Tianyuan
Wang, Xianjin
Gao, Fengbin
Zhong, Shan
Chen, Shanwen
Shen, Zhoujun
Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis
title Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis
title_full Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis
title_fullStr Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis
title_full_unstemmed Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis
title_short Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis
title_sort effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863379/
https://www.ncbi.nlm.nih.gov/pubmed/29562940
http://dx.doi.org/10.1186/s12957-018-1358-x
work_keys_str_mv AT dongfan effectivenessofurinefibronectinasanoninvasivediagnosticbiomarkerinbladdercancerpatientsasystematicreviewandmetaanalysis
AT shenyifan effectivenessofurinefibronectinasanoninvasivediagnosticbiomarkerinbladdercancerpatientsasystematicreviewandmetaanalysis
AT xutianyuan effectivenessofurinefibronectinasanoninvasivediagnosticbiomarkerinbladdercancerpatientsasystematicreviewandmetaanalysis
AT wangxianjin effectivenessofurinefibronectinasanoninvasivediagnosticbiomarkerinbladdercancerpatientsasystematicreviewandmetaanalysis
AT gaofengbin effectivenessofurinefibronectinasanoninvasivediagnosticbiomarkerinbladdercancerpatientsasystematicreviewandmetaanalysis
AT zhongshan effectivenessofurinefibronectinasanoninvasivediagnosticbiomarkerinbladdercancerpatientsasystematicreviewandmetaanalysis
AT chenshanwen effectivenessofurinefibronectinasanoninvasivediagnosticbiomarkerinbladdercancerpatientsasystematicreviewandmetaanalysis
AT shenzhoujun effectivenessofurinefibronectinasanoninvasivediagnosticbiomarkerinbladdercancerpatientsasystematicreviewandmetaanalysis